Protalix BioTherapeutics, Inc.
PLX
$2.22
-$0.14-5.93%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.78M | 18.32M | -5.50M | 2.36M | 164.00K |
| Total Depreciation and Amortization | 406.00K | 404.00K | 387.00K | 372.00K | 360.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 976.00K | 766.00K | 1.37M | 677.00K | 1.14M |
| Change in Net Operating Assets | -15.56M | 2.54M | 5.78M | -7.14M | -6.90M |
| Cash from Operations | -10.40M | 22.03M | 2.03M | -3.73M | -5.23M |
| Capital Expenditure | -593.00K | -761.00K | -403.00K | -498.00K | -431.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.04M | 4.98M | -709.00K | -6.00K | -7.00K |
| Cash from Investing | -3.64M | 4.22M | -1.11M | -504.00K | -438.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 150.00K | 146.00K | 0.00 | 4.10M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 150.00K | 146.00K | 0.00 | 4.10M |
| Foreign Exchange rate Adjustments | 454.00K | -77.00K | -31.00K | -12.00K | 4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.58M | 26.32M | 1.03M | -4.25M | -1.56M |